Publication | Closed Access
The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma
40
Citations
21
References
2013
Year
Hematological MalignancySuperior ActivityMedicineMalignant Blood DisorderClinical RegimensImmunologyPharmacologyImmune Checkpoint InhibitorMultiple MyelomaPharmacotherapyOncologyCancer Research
| Year | Citations | |
|---|---|---|
Page 1
Page 1